Myriad Genetics (MYGN) CFO gets 4,994 performance stock units vesting 2026

Rhea-AI Filing Summary

Myriad Genetics reported an equity award to its Chief Financial Officer, Benjamin Richard Wheeler. On February 2, 2026, he acquired 4,994 shares of common stock at $0 per share, linked to previously granted performance-based restricted stock units (PSUs). These PSUs were originally granted on March 15, 2023, and the Compensation and Human Capital Committee set the final award amount based on performance metrics. Each PSU converts into one share of common stock and will vest on March 15, 2026. After this transaction, Wheeler beneficially owned 97,624 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wheeler Benjamin Richard

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		4,994(1)	A	$0	97,624	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of performance-based restricted stock units (PSUs) initially granted on March 15, 2023, subject to accomplishment of pre-determined performance metrics. On February 2, 2026, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 15, 2026.

Remarks:

	By: Justin Hunter For: Benjamin R. Wheeler	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MYGN CFO Benjamin Wheeler report on this Form 4?

Benjamin Wheeler reported acquiring 4,994 shares of Myriad Genetics common stock at $0 per share. These shares resulted from performance-based restricted stock units that converted into stock after pre-determined performance metrics were evaluated and certified by the company’s Compensation and Human Capital Committee.

How many Myriad Genetics (MYGN) shares does the CFO own after this transaction?

After this transaction, Myriad Genetics CFO Benjamin Wheeler beneficially owned 97,624 shares of common stock directly. This total includes the 4,994 shares tied to performance-based restricted stock units that were awarded based on the company’s achievement of pre-set performance metrics and subsequent committee determination.

What are the key terms of the 4,994 PSUs reported by MYGN’s CFO?

The 4,994 performance-based restricted stock units were initially granted on March 15, 2023, subject to performance metrics. Each PSU represents a contingent right to receive one Myriad Genetics common share and will vest on March 15, 2026, following the committee’s determination of final award amounts.

When were the performance criteria for the MYGN CFO’s PSUs finalized?

The performance criteria were finalized on February 2, 2026, when the Compensation and Human Capital Committee determined the final award amount. Their decision was based on how well Myriad Genetics met the pre-determined performance metrics tied to the PSUs originally granted on March 15, 2023.

Did the MYGN CFO pay anything for the 4,994 shares acquired?

No cash payment was made for these 4,994 shares; they were acquired at a price of $0 per share. The shares resulted from the vesting determination of performance-based restricted stock units that convert into common stock once specified performance conditions and committee approvals are satisfied.